Enara Bio

Exploiting the genomic dark matter for cancer-specific T cell antigen discovery

Enara Bio has developed an innovative immunopeptidomics and bioinformatics platform for the discovery of a novel and differentiated class of cancer-specific targets from the genomic dark matter, coined ‘Dark Antigens’. Dark Antigens are presented across solid tumor types, shared across patients, immunogenic and homogenously expressed within tumors. Enara Bio is developing an internal pipeline of TCR-directed immunotherapies targeting Dark Antigens with a proprietary format and working with big pharma through partnerships.